Avidity Biosciences, Inc. is set to be acquired by Novartis AG for approximately $12 billion, following the separation of its early-stage programs into a new publicly traded company.

Information on the Target

Avidity Biosciences, Inc. (Nasdaq: RNA) is a biopharmaceutical company focused on pioneering a novel class of RNA therapeutics known as Antibody Oligonucleotide Conjugates. This innovative technology aims to offer targeted treatment options, particularly in areas where traditional therapies have been less effective. Avidity's commitment to advancing precision medicine has positioned it as a significant player in the evolving landscape of biopharmaceuticals.

As part of a strategic restructuring, Avidity plans to separate its early-stage precision cardiology programs into a new entity referred to as SpinCo. This spin-off is projected to become a publicly traded company, allowing Avidity to focus its resources on its core therapeutic development and innovation activities.

Industry Overview in the Target’s Specific Country

The biopharmaceutical industry in the United States is one of the most dynamic sectors of the economy, characterized by rapid innovation and substantial investment. With a growing emphasis on personalized medicine, companies are increasingly de